<DOC>
	<DOCNO>NCT01988584</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness two type stem cell , ( either bank cord blood bone marrow ) , child age 2 10 year CP . 15 child bank cord blood CBR 15 child without bank cord blood enrol study . The study involve one baseline/treatment visit 3 follow-up visit 6 month , 12 month , 2 year . Five child group randomize placebo control group baseline/treatment visit . Parents tell child receive stem cell placebo 12 month follow-up visit . At time parent may elect child receive stem cell treatment ; either bone morrow harvest umbilical cord blood bank CBR . All study visit conduct UTHealth Medical School Children 's Memorial Hermann Hospital Houston , Texas . As 1/21/2014 meet enrollment limit child without bank cord blood undergo bone marrow harvest stem cell .</brief_summary>
	<brief_title>Safety Effectiveness Banked Cord Blood Bone Morrow Stem Cells Children With Cerebral Palsy ( CP ) .</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<criteria>1 . Children diagnosis Cerebral Palsy ( spastic CP due periventricular white matter damage neonatal brain injury perinatal stroke intraventricular hemorrhage ) 2 . Gross Motor Function Classification Score level IIV 3 . Ages 24 month 10 year 4 . English speaking , verbal 5 . Ability travel Houston treatment followup 1 . Known history : Intractable seizure Traumatic brain injury Genetic disorder ( demonstrate newborn screen genetic diagnostic testing ) Recently treat current infection Renal insufficiency alter renal function ( define serum creatinine &gt; 1.5 mg/dl screen ) Hepatic disease alter liver function ( define SGPT &gt; 150 U/L [ noncontusion relate ] , and/or T. Bilirubin &gt; 1.3 mg/dL screen ) HIV+ ( demonstrate positive blood test ) Immunosuppression ( define WBC &lt; 3,000 cells/ml screen ) Infectious related neurological injury Sensitivity Ethylene Oxide ( EtO ) [ find fumigant disinfectant ] 2 . If Athetoid CP diagnosis , etiology degenerative , mitochondrial , metabolic disorder must exclude , outcome assessment must able conducted assess potential treatment effect 3 . Normal brain MRI 4 . Evidence acute illness time infusion , , limit , fever ( temperature &gt; 37.5 C ) , vomit , diarrhea , wheeze crackle 5 . Progressing neurological disease ( define Batten Disease , Leukodystrophies , Metabolic disorder , Mitochondrial disorder , Neurotransmitter disorder ) 6 . Microcephaly , macrocephaly , cortical malformation , genetic disorder dysgenesis brain malformation due infection metabolic disorder 7 . Pulmonary disease require ventilator support 8 . If hUCB candidate , bank cord cell total &lt; 10 million/kg 9 . If hUCB candidate , positive maternal infectious disease test ( Hepatitis A , Hepatitis B , HIV 1 , HIV 2 , HTLV 1 , HTLV 2 , Syphilis ) 10 . If hUCB candidate , cord blood sample contamination 11 . Participation concurrent intervention study 12 . Unwillingness return followup visit 13 . Contraindications MRI 14 . Any patient investigator feel opinion study intervention unlikely benefit patient screen failure . 15 . Any patient currently previously enrol clinical stem cell study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cerebral Palsy</keyword>
	<keyword>Brain Injury</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Mononuclear Cells</keyword>
	<keyword>Bone Morrow</keyword>
	<keyword>Umbilical Cord Blood</keyword>
</DOC>